Clinical Trial Update: RC48 Monotherapy or Combination With Envafolimab for CDK12 Alterations mCRPC With Standard Treatment Failure [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial update evaluating RC48 monotherapy or RC48 in combination with Envafolimab for metastatic castration-resistant prostate cancer with C…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Envafolimab (envafolimab)
• RC48 (disitamab vedotin)

Snippet

Sponsor: Tianjin Medical University Second Hospital | Conditions: Prostate Cancer, CDK12 Gene Mutation | Phase 1, Phase 2 | Status: RECRUITING